Page last updated: 2024-09-04

glucagon and ipragliflozin

glucagon has been researched along with ipragliflozin in 1 studies

Compound Research Comparison

Studies
(glucagon)
Trials
(glucagon)
Recent Studies (post-2010)
(glucagon)
Studies
(ipragliflozin)
Trials
(ipragliflozin)
Recent Studies (post-2010) (ipragliflozin)
26,0391,4983,05417545172

Protein Interaction Comparison

ProteinTaxonomyglucagon (IC50)ipragliflozin (IC50)
Sodium/glucose cotransporter 1Homo sapiens (human)1.876
Sodium/glucose cotransporter 2Homo sapiens (human)0.0076

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Anno, M; Fujioka, Y; Imamura, T; Ito, Y; Izawa, S; Kato, M; Kitao, S; Matsumoto, K; Matsuzawa, K; Nakamura, R; Okura, H; Okura, T; Shoji, K; Taniguchi, SI; Ueta, E; Yamamoto, K1

Trials

1 trial(s) available for glucagon and ipragliflozin

ArticleYear
The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
    Scientific reports, 2022, 02-03, Volume: 12, Issue:1

    Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Insulin Resistance; Japan; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome

2022